RYTM Q1 2024 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+126.4% YoY

Gross Profit

$23M89.2% margin

Operating Income

-$140M-538.7% margin

Net Income

-$141M-544.4% margin

EPS (Diluted)

$-2.35

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$81M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$259M

Total Liabilities

$197M

Stockholders' Equity

$62M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$11M	+126.4%
Gross Profit	$23M	$10M	+130.5%
Operating Income	-$140M	-$53M	-166.3%
Net Income	-$141M	-$52M	-170.9%

Revenue Segments

Product

$26M100%